Durability of Response to SARS-CoV-2 BNT162b2 Vaccination in Patients on Active Anticancer Treatment

JAMA Oncol. 2021 Nov 1;7(11):1716-1718. doi: 10.1001/jamaoncol.2021.4390.


This cohort study examines the durability of immune response from BNT162b2 vaccination for severe acute respiratory syndrome coronavirus 2 in patients with cancer vs healthy controls.

Publication types

  • Comment

MeSH terms

  • BNT162 Vaccine
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • SARS-CoV-2*
  • Vaccination


  • COVID-19 Vaccines
  • BNT162 Vaccine